Caveolin-1 Interacts with the Insulin Receptor and Can Differentially Modulate Insulin Signaling in Transfected Cos-7 Cells and Rat Adipose Cells
Fredrik H. Nystrom,
Hui Chen,
Li-Na Cong,
Yunhua Li and
Michael J. Quon
Hypertension-Endocrine Branch National Heart, Lung, and Blood
Institute National Institutes of Health Bethesda, Maryland
20892
 |
ABSTRACT
|
---|
Caveolae may function as microdomains for
signaling that help to determine specific biological actions mediated
by the insulin receptor (IR). Caveolin-1, a major component of
caveolae, contains a scaffolding domain (SD) that binds to a caveolin-1
binding motif in the kinase domain of the IR in vitro. To
investigate the potential role of caveolin-1 in insulin signaling we
overexpressed wild-type (Cav-WT) or mutant (Cav-Mut; F92A/V94A in SD)
caveolin-1 in either Cos-7 cells cotransfected with IR or rat adipose
cells (low and high levels of endogenous caveolin-1, respectively).
Cav-WT coimmunoprecipitated with the IR to a much greater extent than
Cav-Mut, suggesting that the SD is important for interactions between
caveolin-1 and the IR in intact cells. We also constructed several IR
mutants with a disrupted caveolin-1 binding motif and found that these
mutants were poorly expressed and did not undergo autophosphorylation.
Interestingly, overexpression of Cav-WT in Cos-7 cells significantly
enhanced insulin-stimulated phosphorylation of Elk-1 (a
mitogen-activated protein kinase-dependent pathway) while
overexpression of Cav-Mut was without effect. In contrast, in adipose
cells, overexpression of either Cav-WT or Cav-Mut did not affect
insulin-stimulated phosphorylation of a cotransfected ERK2 (but did
significantly inhibit basal phosphorylation of ERK2). Furthermore, we
also observed a small inhibition of insulin-stimulated translocation of
GLUT4 when either Cav-WT or Cav-Mut was overexpressed in adipose cells.
Thus, interaction of caveolin-1 with IRs may differentially modulate
insulin signaling to enhance insulin action in Cos-7 cells but inhibit
insulins effects in adipose cells.
 |
INTRODUCTION
|
---|
The insulin receptor is a member of a large family of
ligand-activated tyrosine kinases that share a number of postreceptor
signaling pathways in common (1, 2, 3). Thus, it is of interest to
elucidate mechanisms contributing to signal specificity after insulin
activates its receptor. Caveolae are flask-shaped invaginations of the
plasma membrane that are abundant in insulin targets such as muscle and
adipose cells and that may contribute to specificity by creating
microdomains for insulin signaling (4, 5, 6). Caveolins are scaffold-like
proteins that form homo- and heterooligomers that are principal
components of caveolae (7, 8). Indeed, overexpression of caveolin-1 is
sufficient to drive formation of caveolae (9). Interestingly, insulin
receptors are enriched in caveolae (5, 10), and the expression of
caveolin, as well as the number of caveolae, increases dramatically
when 3T3-L1 fibroblasts differentiate into adipocytes (11, 12).
Furthermore, phosphorylation of caveolin in response to insulin
stimulation occurs only in differentiated 3T3-L1 adipocytes but not in
undifferentiated fibroblasts, suggesting that caveolin may play a role
in specific metabolic insulin-signaling pathways present in adipocytes
(13, 14). Previous peptide binding studies have shown that the
scaffolding domain of caveolin-1 (residues 82101) binds to a
X
XXXX
motif in the tyrosine kinase domain of the insulin
receptor ß-subunit (where
represents aromatic amino acids at
positions 1193, 1195, and 1200 of the insulin receptor) (15). In
addition, scaffolding domain peptides derived from caveolin-1 or -3 can
increase tyrosine kinase activity of the insulin receptor (10). Some
patients with syndromes of extreme insulin resistance have mutations of
the insulin receptor in which this caveolin binding motif is disrupted
(e.g. W1193L and W1200S) (16, 17, 18, 19, 20, 21). The W1193L mutant
undergoes accelerated degradation resulting in decreased cell surface
expression of receptors and also has an impairment in
autophosphorylation (18, 19, 20, 21). Although the W1200S mutant seems to be
expressed at higher levels on the cell surface than W1193L,
autophosphorylation of this mutant is severely impaired as well (16, 17). Taken together, both in vitro and in vivo
studies suggest that caveolin may interact with the insulin receptor
and play an important role in insulin signaling. However, the
functional consequences of interactions between caveolin and insulin
receptors are not well understood. In the present study, we used
transient transfection techniques to overexpress wild-type and mutant
forms of caveolin-1 in Cos-7 cells (low levels of endogenous
caveolin-1) and rat adipose cells (high levels of endogenous
caveolin-1) to investigate the role of caveolin-1 in insulin signaling.
In addition, we constructed and characterized several insulin receptor
mutants with a disrupted caveolin-1 binding motif. We demonstrate that
the interaction between insulin receptors and caveolin-1 in intact
cells is dependent upon an intact caveolin-1 scaffolding domain.
Intriguingly, we found that overexpression of caveolin-1 enhanced
insulin signaling in Cos-7 cells while inhibiting insulin action in
adipose cells.
 |
RESULTS
|
---|
Overexpression of Caveolin-1 in Cos-7 Cells and Rat Adipose
Cells
To assess overexpression of recombinant caveolin-1 constructs,
lysates derived from transiently transfected Cos-7 cells and rat
adipose cells were immunoblotted with an antibody against caveolin-1
(Fig. 1
). Recombinant caveolin-1 could be
distinguished from the endogenous protein because myc-tagged caveolin-1
migrated more slowly on the gel. We detected abundant endogenous
caveolin-1 in adipose cells while very little of the endogenous protein
was observed in Cos-7 cells. Under our experimental conditions,
transfection efficiencies were approximately 5% for adipose cells (22)
and approximately 30% for Cos-7 cells as determined by expression of
green fluorescent protein (data not shown). Therefore, by comparing the
density of bands representing endogenous and recombinant caveolin-1, we
estimated levels of overexpression of approximately 20-fold in both
Cos-7 cells and adipose cells. A mutant caveolin-1 construct (Cav-Mut)
containing F92A and V94A point mutations in the scaffolding domain of
caveolin-1 was expressed at levels comparable to the wild-type
construct (Cav-WT).

View larger version (14K):
[in this window]
[in a new window]
|
Figure 1. Overexpression of Caveolin-1 in Rat Adipose Cells
and Cos-7 Cells
Cells were transiently transfected with a control plasmid (C =
pCIS2 for adipose cells and pCIS-eGFP for Cos-7 cells), or expression
vectors for myc-tagged caveolin-1 (Cav-WT or Cav-Mut). For Cos-7 cells,
1 µg DNA/well was used while for adipose cells 4 µg DNA/cuvette
were used. Cell lysates derived from each group (30 µg total protein)
were subjected to immunoblotting with an anticaveolin-1 antibody.
Recombinant myc-tagged caveolin-1 migrated more slowly on the gel than
endogenous caveolin. Transfection efficiencies were approximately 5%
for adipose cells and approximately 20% for Cos-7 cells.
|
|
Characterization of Insulin Receptor Constructs
We designed a number of insulin receptor mutants to disrupt the
X
XXXX
caveolin-1 binding motif present in the kinase domain of
the receptor ß-subunit to evaluate potential interactions between
caveolin-1 and the insulin receptor. In the W1200T mutant, the distal
aromatic amino acid in the binding motif has been changed to threonine,
a residue found in a homologous region of c-src (1). The F1195G
mutation disrupts the binding motif at the central aromatic residue
while the triple mutation (W1193G/F1195G/W1200G) replaces all three
aromatic amino acids with glycine. The K1030A mutant is a
kinase-inactive receptor resulting from disruption of the canonical ATP
binding site.
High level expression of the mature 95-kDa insulin receptor ß-subunit
was observed in lysates derived from Cos-7 cells transfected with
either the wild-type or K1030A receptors (Fig. 2A
). However, expression levels for the
caveolin-binding motif mutants were substantially lower. Of the three
binding motif mutants, the highest level of expression was observed
with W1200T. Interestingly, levels of expression for the 210-kDa
proinsulin receptor were similar for all of the insulin receptor
constructs evaluated. Since the extracellular
-subunit was not
altered in any of our constructs, we performed
[125I]insulin binding studies in parallel with our
immunoblotting experiments to determine the relative numbers of
recombinant receptors present on the cell surface. The results of our
binding studies were consistent with our immunoblotting experiments
(Fig. 2
, A and C). That is, the relative number of insulin receptors
present on the cell surface was proportional to the amount of 95-kDa
ß-subunit detected by immunoblotting. When we immunoblotted cell
lysates from experiments shown in Fig. 2A
with an antiphosphotyrosine
antibody we observed normal autophosphorylation of the wild-type
insulin receptor, but we could not detect significant
autophosphorylation with any of the mutant insulin receptors (Fig. 2B
).

View larger version (44K):
[in this window]
[in a new window]
|
Figure 2. Overexpression of Insulin Receptor Constructs in
Cos-7 Cells
Cells were transiently transfected with a control plasmid (pCIS-eGFP)
or expression vectors for wild-type (WT) or various mutant human
insulin receptor constructs (1 µg DNA/well). W1200T, F1195G, and the
triple-mutant (W1193G/F1195G/W1200G) are point mutants in the insulin
receptor ß-subunit that disrupt the caveolin-1 binding motif. The
K1030A mutant is a kinase-inactive receptor. Some cells were used for
[125I]insulin binding studies while other cells were
treated without or with insulin (100 nM, 2 min) and cell
lysates were subjected to SDS-PAGE followed by immunoblotting. A,
Antiinsulin receptor ß-subunit immunoblot. B, Antiphosphotyrosine
immunoblot. The wild-type insulin receptor ß-subunit undergoes
autophosphorylation in response to insulin stimulation while the
various mutant insulin receptors do not. C, Cell surface tracer
[125 I]insulin binding at 4 C. Data shown are the
mean ± SEM of triplicate determinations from a single
experiment using samples that correspond to the experiment shown in
panel B. These experiments were repeated independently at least five
times.
|
|
Interaction between Caveolin-1 and Insulin Receptors in Intact
Cells
To determine whether interactions between caveolin-1 and insulin
receptors can occur in intact cells, we performed coimmunoprecipitation
experiments using lysates derived from Cos-7 cells transiently
cotransfected with both myc-tagged caveolin-1 and insulin receptors
(Fig. 3
). In these cells, Cav-WT was
easily detected in insulin receptor immunoprecipitates (Fig. 3
, lane
3). In contrast, the interaction of the scaffolding-domain mutant
(Cav-Mut) with the wild-type insulin receptor appeared to be
significantly reduced (Fig. 3
, lane 4). Interestingly, significant
coimmunoprecipitation of Cav-WT with the W1200T insulin receptor mutant
was observed even though this receptor has a disrupted
X
XXXX
caveolin-1 binding motif (Fig. 3
, lane 5). Similar to our results with
the wild-type insulin receptor, coimmunoprecipitation of Cav-Mut with
W1200T was significantly impaired (Fig. 3
, lane 6). We also observed
significant coimmunoprecipitation of Cav-WT with a kinase-inactive
insulin receptor mutant (with an intact caveolin binding motif) that
was expressed at levels comparable to the wild-type receptor (data not
shown).

View larger version (35K):
[in this window]
[in a new window]
|
Figure 3. Coimmunoprecipitation of Caveolin-1 and Insulin
Receptors in Transfected Cos-7 Cells
Cells were transiently cotransfected with various combinations of
myc-tagged caveolin constructs and insulin receptor constructs (1 µg
of each plasmid/well). Whole cell lysates were immunoprecipitated with
an antibody against the ß-subunit of the insulin receptor followed by
immunoblotting with either an anti-myc antibody to detect
coimmunoprecipitation of caveolin-1 (upper panel, lanes
16), or an antiinsulin receptor ß-subunit antibody to verify
comparable immunoprecipitation efficiency (lower panel,
lanes 16). Lanes 712 show the levels of caveolin and insulin
receptor expression present in cell lysates before immunoprecipitation.
|
|
We performed similar coimmunoprecipitation experiments in rat adipose
cells transiently transfected with Cav-WT or Cav-Mut (Fig. 4
). Since adipose cells express high
levels of endogenous insulin receptors, it was not necessary to
cotransfect the cells with recombinant insulin receptors. Consistent
with our results in Cos-7 cells, Cav-WT coimmunoprecipitated with
insulin receptors much better than Cav-Mut (Fig. 4
, lanes 36). In
addition, insulin stimulation did not alter the ability of Cav-WT to
coimmunoprecipitate with the insulin receptor (Fig. 4
, lanes 34). We
observed similar coimmunoprecipitation of endogenous insulin receptors
with endogenous caveolin-1 in freshly isolated untransfected adipose
cells (data not shown). Taken together, our results from both Cos-7
cells and adipose cells are consistent with the hypothesis that
interactions between caveolin-1 and insulin receptors in intact cells
depend upon the caveolin-1 scaffolding domain.

View larger version (27K):
[in this window]
[in a new window]
|
Figure 4. Coimmunoprecipitation of Insulin Receptors and
Caveolin-1 from Rat Adipose Cells
Cells were transiently transfected with a control plasmid (pCIS2) or
myc-tagged caveolin-1 constructs (Cav-WT or Cav-Mut) (4 µg
DNA/cuvette). After transfection, cells were treated without or with
insulin (100 nM, 2 min), and membrane fractions were
subjected to immunoprecipitation with an antibody against the
ß-subunit of the insulin receptor. Samples were then immunoblotted
with either an anti-myc antibody to detect coimmunoprecipitation of
caveolin-1 (upper panel, lanes 16) or an antiinsulin
receptor ß-subunit antibody to verify comparable immunoprecipitation
efficiency (lower panel, lanes 16). Lanes 712 show
the levels of caveolin-1 and insulin receptor present in cell membrane
fractions before immunoprecipitation.
|
|
Functional Consequences of Overexpression of Caveolin-1 in Cos-7
Cells
We used the Path-Detect kit from Stratagene (La
Jolla, CA) to assess effects of overexpression of caveolin-1 on
insulin-induced Elk-1 phosphorylation in Cos-7 cells. In this assay,
phosphorylation of a transfected GAL4 binding domain/Elk-1 activation
domain fusion protein binds and activates a cotransfected GAL4 binding
sequence/luciferase reporter plasmid resulting in increased luciferase
expression. We observed a 4-fold increase in Elk-1 phosphorylation upon
insulin stimulation of control cells overexpressing wild-type insulin
receptors (Fig. 5A
). Interestingly,
co-overexpression of Cav-WT significantly enhanced insulin-stimulated
phosphorylation of Elk-1 to levels approximately twice those observed
in the control cells. In contrast, overexpression of Cav-Mut did not
significantly affect phosphorylation of Elk-1, suggesting that the
ability of Cav-WT to modulate insulin signaling is dependent upon an
intact scaffolding domain. In some experiments [125
I]insulin binding studies and anti-myc immunoblots were performed in
parallel to confirm comparable overexpression of recombinant insulin
receptors and caveolin constructs in all groups (data not shown). In
contrast to cells overexpressing wild-type insulin receptors, Elk-1
phosphorylation did not significantly increase upon insulin stimulation
of cells overexpressing the K1030A kinase-inactive insulin receptor
mutant (Fig. 5B
). Co-overexpression of Cav-WT or Cav-Mut with the
K1030A receptor did not significantly change Elk-1 phosphorylation in
either the absence or the presence of insulin. We obtained similar
results from cells overexpressing the W1200T mutant insulin receptor as
might be expected from a receptor that does not undergo
autophosphorylation (data not shown).

View larger version (23K):
[in this window]
[in a new window]
|
Figure 5. Insulin-Stimulated Phosphorylation of Elk-1 in
Cos-7 Cells Overexpressing Caveolin-1 and Insulin Receptors
The PathDetect kit was used to investigate effects of caveolin-1 on
Elk-1 phosphorylation as described in Materials and
Methods. Cells were transiently cotransfected with pFA-Elk
(0.025 µg DNA/well), pFR-Luc (0.5 µg DNA/well), a caveolin
construct (0.5 µg DNA/well), and an insulin receptor construct (0.5
µg DNA/well). After overnight serum starvation, cells were treated
without or with insulin (100 nM, 6 h) and the
luciferase activity in each sample was determined. A, Coexpression of
wild-type, but not mutant, caveolin-1 with wild-type insulin receptor
significantly enhanced insulin-stimulated phosphorylation of Elk-1
(P < 0.007). Results shown are the mean ±
SEM of nine independent experiments performed in triplicate
(normalized to the group transfected with wild-type insulin receptors
and stimulated with insulin). B, Insulin did not stimulate Elk-1
phosphorylation in Cos-7 cells overexpressing the kinase-inactive
insulin receptor mutant K1030A. Coexpression of wild-type or mutant
caveolin-1 with the K1030A insulin receptor mutant had no effect on
Elk-1 phosphorylation. Results shown are the mean ±
SEM of five independent experiments performed in
triplicate. Data were normalized to the group transfected with
wild-type insulin receptors and stimulated with insulin and also
corrected for the level of cell surface insulin binding.
|
|
To further investigate the effects of caveolin-1 on insulin signaling
in Cos-7 cells we assessed insulin-stimulated extracellular
signal-regulated kinase-2 (ERK2) phosphorylation in cells
cotransfected with insulin receptors, hemagglutinin (HA)-tagged
ERK2, and either Cav-WT or Cav-Mut (Fig. 6
). Similar to our results with Elk-1,
insulin stimulated a significant increase in ERK-2 phosphorylation in
control cells (Fig. 6A
, lanes 12). However, in contrast to our
results with Elk-1, overexpression of Cav-WT blocked the ability of
insulin to stimulate ERK2 phosphorylation (Fig. 6A
, lanes 34).
Nevertheless, this effect of Cav-WT appeared to depend upon an intact
scaffolding domain because insulin-stimulated phosphorylation of ERK-2
in cells overexpressing Cav-Mut was similar to that of the control
cells (Fig. 6A
, lanes 56).

View larger version (35K):
[in this window]
[in a new window]
|
Figure 6. Insulin-Stimulated Phosphorylation of ERK2 in
Transfected Cos-7 Cells
Cells were cotransfected with constructs for HA-tagged ERK2, human
insulin receptor, and either a control plasmid or caveolin constructs.
After transfection, cells were treated without or with insulin (100
nM, 4 min), and whole-cell lysates were prepared. A,
Lysates were immunoprecipitated with anti-HA antibody (HA-11) followed
by immunoblotting with antiphospho-MAPK antibodies (upper
panel) or HA-11 (lower panel). A representative
blot is shown from an experiment that was performed independently
twice. B, As a control experiment to verify comparable expression of
the caveolin constructs, lysates were immunoblotted with anti-myc
antibodies.
|
|
Functional Consequences of Overexpression of Caveolin-1 in Adipose
Cells
Adipose cells cotransfected with caveolin-1 constructs and an
HA-tagged ERK2 were treated without or with insulin, and
phosphorylation of recombinant ERK2 was assessed by immunblotting
anti-HA immunoprecipitates with an anti-phospho-mitogen-activated
protein kinase (MAPK) antibody (Fig. 7A
, upper panel). In the
absence of insulin, ERK2 was phosphorylated at a detectable level in
control cells cotransfected with an empty expression vector (pCIS2) and
HA-ERK2. Upon insulin stimulation, we observed an approximately 3-fold
increase in ERK2 phosphorylation (Fig. 7A
, lanes 12; Fig. 7C
).
Co-overexpression of either Cav-WT or Cav-Mut resulted in a significant
approximately 3-fold decrease in basal ERK2 phosphorylation (in the
absence of insulin) (Fig. 7A
, lanes 3 and 6; Fig. 7C
). No significant
differences in the level of ERK2 phosphorylation were observed between
any of the groups in the presence of insulin (Fig. 7A
, lanes 2, 4, and
6; Fig. 7C
). Note that cell lysates used in these experiments did not
include the nuclear fraction so that the amount of ERK2 recovered in
anti-HA immunoprecipitates was slightly less in the samples derived
from insulin-stimulated cells (presumably because some of the ERK2
underwent translocation to the nucleus upon insulin stimulation) (Fig. 7A
, lower panel). As a control experiment, we verified
comparable expression of the various transgenes in each experimental
group by immunoblotting cell lysates with antibodies against either the
HA epitope (Fig. 7B
, upper panel) or the Myc epitope (Fig. 7B
, lower panel). Interestingly, when anti-HA
immunoprecipitates were immunblotted with an antibody against myc, we
detected comparable coimmunoprecipitation of Cav-WT or Cav-Mut with
HA-ERK2 that was unaffected by treatment of the cells with insulin
(Fig. 8
). These results suggested that
interactions between ERK2 and caveolin-1 do not depend on the
caveolin-1 scaffolding domain (in contrast to interactions with the
insulin receptor). Thus, interactions of caveolin-1 with ERK2 may help
to explain why overexpression of either Cav-WT or Cav-Mut inhibits
basal phosphorylation of ERK2 in adipose cells.

View larger version (28K):
[in this window]
[in a new window]
|
Figure 7. Insulin-Stimulated Phosphorylation of ERK2 in
Transfected Rat Adipose Cells
Cells were cotransfected with an HA-tagged ERK2 construct (1 µg
DNA/cuvette) and either a control plasmid or caveolin constructs (4
µg DNA/cuvette). After transfection, cells were treated without or
with insulin (100 nM, 4 min), and whole-cell lysates were
prepared. A, Lysates were immunoprecipitated with anti-HA antibody
(HA-11) followed by immunoblotting with HA-11 or antiphospho-MAPK
antibodies. A representative blot is shown from an experiment that was
performed independently five times. B, As a control experiment to
verify comparable expression of the various constructs, lysates were
immunoblotted with antibodies against either HA (to detect recombinant
ERK2) or Myc (to detect recombinant caveolin). C, Results of
quantifying phosphorylated HA-tagged ERK2 from five independent
experiments (means ± SEM) similar to the one shown in
panel A. The basal level of ERK2 phosphorylation was significantly
decreased in cells overexpressing either Cav-WT or Cav-Mut when
compared with the control group (P < 0.05). There
was no significant difference between groups in the levels of
insulin-stimulated ERK2 phosphorylation.
|
|

View larger version (18K):
[in this window]
[in a new window]
|
Figure 8. Coimmunoprecipitation of ERK2 and Caveolin-1 in Rat
Adipose Cells
Cells were cotransfected with HA-ERK2 (1 µg DNA/cuvette) and a
control plasmid (pCIS2), Cav-WT, or Cav-Mut (4 µg DNA/cuvette). After
transfection, cells were treated without or with insulin (100
nM, 4 min) and whole-cell lysates were immunoprecipitated
with HA-11 followed by immunoblotting with HA-11 or Myc antibodies
(lanes 16). As a control experiment to verify comparable expression
of the various constructs, lysates were immunoblotted with antibodies
against either HA (to detect recombinant ERK2), or Myc (to detect
recombinant caveolin) (lanes 712).
|
|
We examined the effects of overexpressing caveolin-1 on actions of
insulin that are unrelated to MAPK-dependent pathways by studying
insulin-stimulated translocation of GLUT4 in transfected rat adipose
cells (Fig. 9
). We observed an
approximately 2-fold recruitment of GLUT4 to the cell surface in
response to insulin stimulation in control cells cotransfected with
pCIS2 and GLUT-HA. Interestingly, overexpression of either Cav-WT or
Cav-Mut caused a small, but statistically significant, decrease in the
insulin dose-response curves (when compared with the control).

View larger version (20K):
[in this window]
[in a new window]
|
Figure 9. Insulin-Stimulated Recruitment of GLUT4-HA to the
Cell Surface of Adipose Cells Overexpressing Cav-WT or Cav-Mut
Data are expressed as a percentage of cell surface GLUT4 in the
presence of a maximally effective insulin concentration for the control
group. A, Recruitment of epitope-tagged GLUT4 to the cell surface of
cells cotransfected with Cav-WT/GLUT4-HA (4 µg and 1 µg
DNA/cuvette, respectively) () was decreased compared with the
control group ( ). Results shown are the means ±
SEM of six independent experiments. The best-fit curve for
the control group had an ED50 = 0.07 nM.
The best-fit curve for the Cav-WT group had an ED50 =
0.12 nM. The difference in the two curves was statistically
significant by multivariate ANOVA (P < 1 x
10-5). B, Recruitment of epitope-tagged GLUT4 to the cell
surface of cells cotransfected with Cav-Mut/GLUT4-HA () was
decreased compared with the control group ( ). The difference in the
two curves was statistically significant by multivariate ANOVA
(P < 1 x 10-6). The best-fit
curve for the control group had an ED50 = 0.10
nM. The best-fit curve for the Cav-Mut group had an
ED50 = 0.05 nM. Results are the means
± SEM of seven independent experiments.
|
|
 |
DISCUSSION
|
---|
Characterization of Caveolin-1 and Insulin Receptors in Intact
Cells
We studied interactions between insulin receptors and
overexpressed Cav-WT or Cav-Mut in Cos-7 cells and rat adipose cells.
The F92A and V94A mutations introduced into our Cav-Mut construct were
designed to disrupt the binding of caveolin-1 to
X
XXXX
caveolin-1 binding motifs. The choice of these mutations was based upon
alanine scanning mutagenesis studies of interactions between caveolin-1
peptides and the epidermal growth factor receptor (15). Previous
peptide binding studies demonstrated that the scaffolding domain of
caveolin-1 (residues 82101) interacts specifically with the caveolin
binding motif present in the ß-subunit of the insulin receptor as
well as a number of other receptor tyrosine kinases and downstream
signaling molecules (8, 10, 15). In addition, the insulin receptor is
enriched in subcellular fractions containing caveolae (23, 24). In
keeping with these previous studies, our coimmunoprecipitation
experiments showed, for the first time, that the full- length insulin
receptor and caveolin-1 can interact in intact cells. While insulin
stimulation did not result in any detectable change in this
interaction, the markedly impaired ability of Cav-Mut to
coimmunoprecipitate with the insulin receptor suggests that
interactions between insulin receptors and caveolin-1 depend upon the
caveolin-1 scaffolding domain. Our results are consistent with a direct
interaction in intact cells between the scaffolding domain of
caveolin-1 and the caveolin binding motif in the insulin receptor.
As a complementary approach to studying interactions between the
insulin receptor and caveolin-1, we generated several insulin receptor
mutants with a disrupted caveolin binding motif (residues 11931200;
WSFGVVLW).
This region of the receptor is likely to be important for signaling
because it is located just distal to the three critical tyrosine
phosphorylation sites in the activation loop of the kinase domain
(residues 1158, 1162, and 1163) (25) and is also well conserved in
homologous regions of many other tyrosine kinases (2). We were unable
to detect insulin-stimulated autophosphorylation of any of our mutant
receptors. Moreover, it was difficult to evaluate interactions of
caveolin-1 with the W1193G receptor mutant and the W1193G/F1195G/W1200G
triple mutant because mature insulin receptors were poorly expressed on
the cell surface for these constructs (although the proreceptor seemed
to be present). Thus, the region of the insulin receptor containing the
caveolin-1 binding motif may be necessary for the catalytic function of
the kinase domain and may also be important for normal
posttranslational receptor processing. Interestingly, these results are
consistent with previous characterizations of a similar naturally
occurring human insulin receptor mutation (W1193L) that has impaired
autophosphorylation, undergoes accelerated degradation of the
proreceptor (due to binding heat shock protein 90), and has markedly
decreased cell surface expression (18, 19, 21).
To avoid potential problems with abnormal folding that may be occurring
with the W1193G receptor and the triple mutant, we designed a W1200T
mutant that disrupts the caveolin binding motif by mimicking the
homologous region of c-src (WSFGILLT in region IX of the kinase
domain). Although the WSFGILLT sequence in c-src does not perfectly
match the canonical caveolin binding motif (15), the scaffolding domain
of caveolin-1 is known to interact directly with c-src (26). It remains
possible that this imperfect motif may also bind to the scaffolding
domain of caveolin-1 since the region of c-src that binds to caveolin-1
has not been elucidated. For example, the reductase domain of
endothelial nitric oxide synthase (eNOSr) also does not contain a known
caveolin binding motif, but caveolin-1 binds to eNOSr and the
scaffolding domain of caveolin-1 inhibits eNOSr activity (27). We
observed significant coimmunoprecipitation of Cav-WT with the W1200T
insulin receptor mutant while interaction with Cav-Mut was
significantly impaired. Thus, similar to interactions between wild-type
insulin receptors and caveolin-1, the scaffolding domain of caveolin-1
is important for binding to the W1200T receptor. Our results also
suggest that either the canonical caveolin-1 binding motif is not
strictly required for the insulin receptor to bind caveolin-1 or that
caveolin-1 is capable of binding to another region of the insulin
receptor. Although the W1200T receptor was not expressed as well as the
wild-type receptor, it did achieve higher levels of expression than the
W1193G mutant or triple-mutant. Similar to our other two receptor
mutants, W1200T also had impaired autophosphorylation. This was
intriguing because a threonine residue in the homologous position of
c-src does not interfere with catalytic activity. Nevertheless, a
similar naturally occurring insulin receptor mutation (W1200S) that
causes severe insulin resistance in a dominant fashion is also kinase
inactive (16, 17).
Functional Consequences of Overexpression of Caveolin-1
We chose to explore the functional role of caveolin-1 in insulin
signaling in both Cos-7 cells that express little endogenous caveolin-1
as well as in rat adipose cell that express high levels of caveolin-1.
Terminally differentiated cells including classical insulin targets
such as skeletal muscle and adipose cells often have abundant caveolae
and high levels of endogenous caveolin (8). In contrast,
undifferentiated or dedifferentiated transformed cells usually have few
or no caveolae and lower levels of caveolin (11, 12, 28). Oncogenic
transformation by activated Neu lowers the level of endogenous
caveolin-1 in fibroblasts (29). Moreover, down-regulation of caveolin-1
by stable transfection of antisense constructs in NIH 3T3 cells results
in increased cellular transformation (30). Conversely, overexpression
of recombinant caveolin-1 in transformed cells results in reversion of
this phenotype (31). This negative correlation between caveolin-1
expression and cellular transformation suggests that caveolin-1 may
have an inhibitory effect on growth factor or oncogenic signaling.
Interestingly, caveolin-1 only binds to wild-type Ras and c-src but not
to activated Ras or v-src, and overexpression of caveolin-1 inhibits
c-src autophosphorylation in transfected 293T cells (26, 32).
Furthermore, numerous studies suggest that interactions between
caveolin and a variety of signaling molecules, including G proteins,
src family kinases, and growth factor receptors, may serve to sequester
inactive signaling molecules and inhibit signaling (for review see Ref.
8). Thus, caveolin-1 seems to generally function in an inhibitory role
in most studies. However, there is some evidence that the role of
caveolins in cellular signaling may be cell type dependent and more
diverse than previously appreciated. For example, the development of
multidrug resistance in some tumor cell lines has been associated with
up-regulation of caveolin-1 and caveolae (33, 34), while suppression of
caveolin-1 in androgen-insensitive metastatic murine prostate cancer
cells leads to a more differentiated phenotype that responds to
androgens by undergoing apoptosis (35).
In Cos-7 cells transiently transfected with insulin receptors,
overexpression of Cav-WT resulted in a significant increase in the
ability of insulin to phosphorylate Elk-1 (while overexpression of
Cav-Mut was without effect). This was dependent upon the presence of a
catalytically active insulin receptor since cells expressing the
kinase-inactive mutants K1030A or W1200T did not phosphorylate Elk-1 in
response to insulin (in either the absence or presence of recombinant
caveolin-1). Although our results do not fit with the paradigm of
caveolin acting as an inhibitor of signaling, they are in agreement
with a recent report demonstrating that overexpression of caveolin-3
may activate the insulin receptor kinase in HEK293T cells (10). That
study also showed that scaffolding-domain peptides from caveolin-1 or
-3 can bind and activate the insulin receptor kinase in
vitro. Taken together with our demonstration that the insulin
receptor binds to caveolin-1 in intact cells, it seems likely that our
Elk-1 phosphorylation results are explained, at least in part, by
interaction of caveolin-1 with the insulin receptor. It is also
possible that the scaffolding domain of caveolin-1 mediates
interactions with other insulin-signaling proteins to enhance Elk-1
phosphorylation. Indeed, previous studies have demonstrated that
signaling molecules related to Elk-1 phosphorylation, such as Ras, Raf,
MAPK/ERK kinase, and ERK2, are associated with caveolae (36) and
caveolin-1 can bind to Ras (32) and ERK2 (this study). However, these
interactions seem less likely to explain our results because the
binding of caveolin-1 to these molecules may sequester inactive forms
and tend to inhibit signaling (8). Indeed, in Cos-7 cells,
overexpression of Cav-WT suppressed insulin-stimulated phosphorylation
of ERK-2 while overexpression of Cav-Mut was without effect on ERK2
phosphorylation.
To study effects of overexpression of caveolin-1 on MAPK-dependent
pathways in rat adipose cells, we examined phosphorylation of a
cotransfected ERK2 in response to insulin stimulation. In contrast to
our results in Cos-7 cells, overexpression of either Cav-WT or Cav-Mut
decreased the basal level of ERK2 phosphorylation (in the absence of
insulin) but was without effect on insulin-stimulated phosphorylation.
It is unlikely that these results are explained by interactions of
caveolin-1 with the insulin receptor since overexpression of Cav-Mut
(which does not bind well to the insulin receptor) yielded similar
results. Somewhat surprisingly, we found that both Cav-WT and Cav-Mut
coimmunoprecipitated with ERK2 in adipose cells. Furthermore, this
interaction was not affected by treating the cells with insulin. When
we scanned the amino acid sequence of human ERK2, we could not identify
any known caveolin scaffolding-domain binding motifs. Taken together,
these findings suggest that an intact scaffolding domain may not be
necessary for interactions of caveolin-1 with ERK2 in adipose
cells.
When we investigated effects of overexpression of caveolin-1 on a
MAPK-independent function in rat adipose cells, we found that both
Cav-WT and Cav-Mut caused a small decrease in insulin-induced
translocation of GLUT4. Since both the wild-type and mutant caveolin
mediated a similar effect, it is unlikely that this was caused by
interactions of the caveolin-scaffolding domain with the insulin
receptor. Downstream effectors of insulin action that have been
implicated in mediating recruitment of GLUT4 to the cell surface such
as PKC-
(37) are also known to interact with caveolin. However,
these interactions are also unlikely to explain our data because the
scaffolding domain of caveolin-1 inhibits PKC-
activity (38), and
our effects are observed with both Cav-WT and Cav-Mut.
It is interesting that in adipose cells, overexpression of either
Cav-WT or Cav-Mut had inhibitory effects on both MAPK-dependent and
-independent pathways while in Cos-7 cells, Cav-WT enhanced some
insulin-stimulated MAPK-dependent pathways. This differential
modulation of signaling may be due to differences in endogenous levels
of caveolin-1. For example, since caveolin peptides have been shown to
enhance insulin receptor tyrosine kinase activity (10), overexpression
of caveolin in cells that have low endogenous levels of caveolin might
be predicted to enhance insulin signaling as we observed. However, if
the cell already has high endogenous levels of caveolin, its
interaction with the insulin receptor may be saturated, and
overexpression of caveolin may interfere with other downstream
effectors. In addition, it is possible that other proteins that are
important for the ability of caveolin to modulate signaling may be
expressed in a cell type-dependent fashion. For example, insulin
stimulation results in tyrosine phosphorylation of caveolin-1 by fyn
only in 3T3-L1 adipocytes but not in undifferentiated preadipocytes
(13, 39). A kinase that is induced upon adipocyte differentiation has
been implicated in phosphorylation of c-cbl, which can then activate
fyn leading to phosphorylation of caveolin (13).
Conclusions
Interactions between caveolin-1 and insulin receptors in intact
cells are dependent upon the caveolin-1 scaffolding domain. Point
mutations disrupting the caveolin-1 binding motif in the insulin
receptor result in markedly decreased cell surface receptor expression
and a defect in receptor autophosphorylation consistent with a
functionally important role for this region of the insulin receptor.
Indeed, a number of patients with syndromes of extreme insulin
resistance have mutations in this very region. Finally, our data
suggest that caveolin may have both inhibitory and stimulatory roles in
insulin signaling that depend upon the cellular context.
 |
MATERIALS AND METHODS
|
---|
Expression Plasmids
pCIS2: Cytomegalovirus (CMV)-based parent expression vector that
generates high levels of expression in adipose cells and Cos-7 cells
(40, 41).
Cav-WT: HindIII/BamH I fragment (
600-bp)
containing cDNA for myc-tagged canine caveolin-1 [obtained from M.
Lisanti (7, 42)] was blunt-ended and ligated in the sense orientation
into the HpaI site of pCIS2.
Cav-Mut: F92A and V94A point mutations in the scaffolding domain of
caveolin-1 were introduced into Cav-WT using the mutagenic
oligonucleotide 5'-CTT CAC CAC CGC CAC
TGC GAC AAA ATA C-3' and the Morph mutagenesis
kit (5Prime
3Prime; Boulder, CO). This mutagenesis also causes a loss
of a Tsp 45 I restriction site.
hIR-WT: pCIS2 vector containing the cDNA for the human insulin receptor
(22).
hIR-K1030A: kinase-inactive point mutant of hIR-WT (obtained from S.I.
Taylor)
hIR-W1200T: W1200T point mutant of hIR-WT generated using the mutagenic
oligonucleotide 5'-GGC GTG GTC CTT ACC GAA ATC
ACT AGC TTG GC-3'. This oligonucleotide also
introduced a silent mutation that created an extra restriction site for
Bfa I.
hIR triple-mutant: mutant of hIR-WT containing W1193G, F1195G, and
W1200G mutations to disrupt
X
XXXX
caveolin binding motif. The
mutagenic oligonucleotide 5'-CAC TTC TTC TGA CAT
GGG GTC CGG TGG
CGT GGT CCT TGG GGA AAT CAC-3' used also causes
loss of a Bsplu 11 restriction site.
hIR-F1195G: mutant derived from hIR-triple mutant using mutagenic
oligonucleotide 5'-CTG ACA TGT GGT CCG GTG GCG
TGG TCC TTT GGG AAA TCA CCA GC-3' which
changes back F1193 and W1200 and also restores the restriction site for
Bsplu 11.
PCIS2-GLUT4 HA: the expression vector for GLUT4-HA was constructed as
described previously (43).
HA-ERK2: expression vector for HA-tagged ERK2 (gift from M. Cobb).
The presence of correct mutations in the various constructs was
verified by direct sequencing.
Antibodies
Murine monoclonal antibodies directed against phosphotyrosine
(4G10) were obtained from Upstate Biotechnology, Inc.
(Lake Placid, NY). Polyclonal antibodies against the myc epitope and
the insulin receptor ß-subunit were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Monoclonal antibodies
against caveolin-1 (no. 13620) were obtained from Transduction Laboratories, Inc. (Lexington, KY). Phospho-MAPK antibodies were
obtained from New England Biolabs, Inc. (Beverly, MA) and
monoclonal antibodies against the HA epitope (HA-11) were obtained from
BabCO (Berkeley, CA).
Transient Transfection of Cos-7 Cells
Cos-7 cells were cultured in DMEM supplemented with 25
mM glucose, 20 mM glutamine, 100 U/ml
penicillin G, 100 µg/ml streptomycin, and 10% FCS at 37 C, 5%
CO2. Lipofectamine Plus (Life Technologies, Inc., Gaithersburg, MD) was used to transfect cells at
approximately 80% confluency in six-well dishes according to the
manufacturers protocol.
Transient Transfection of Rat Adipose Cells and Assay for Cell
Surface Epitope-Tagged GLUT4
Isolated adipose cells from epididymal fat pads of male rats
(170200 g, CD strain) were transfected by electroporation as
described previously (41, 44). To assess effects of insulin on
translocation of GLUT4, groups of cells were transfected with an empty
expression vector pCIS2 alone or cotransfected with GLUT4-HA and pCIS2,
Cav-WT, or Cav-Mut. Twenty hours after electroporation, adipose cells
were treated with insulin at 37 C for 30 min. Cell surface
epitope-tagged GLUT4 was quantified by using the anti-HA mouse
monoclonal antibody HA-11 in conjunction with 125I-labeled
sheep antimouse IgG as described (22).
Immunoprecipitation and Immunoblotting
For Cos-7 cells, lysates were prepared by washing cells with PBS
and then scraping the cells in ice-cold RIPA buffer on ice (20
mM Tris-HCl, pH 7.4, 2.5 mM EDTA, 50
mM NaF, 1 mM sodium orthovanadate, 1% Triton
X-100 and 0.1% SDS, and a protease inhibitor cocktail (Complete
Tablet, Boehringer Mannheim, Mannheim, Germany)).
For some experiments, transfected cells were serum starved overnight
and then treated without or with insulin (100 nM, 2 min)
followed by freezing on liquid nitrogen. Cell lysates were then
prepared as described above. Lysates were centrifuged at 10,000 x
g for 10 min to pellet cellular debris. For
immunoprecipitation with the antiinsulin receptor ß-subunit antibody,
0.6 µg antibody and prewashed protein A-agarose (5% of the total
volume) were mixed with each sample (300 µg total protein) at 4 C on
a rotating wheel overnight. The immune complexes were washed three
times with RIPA buffer, and samples were pelleted by centrifugation and
eluted by boiling in Laemmli sample buffer for 5 min followed by
SDS-PAGE and immunoblotting with various antibodies. For adipose cells,
whole cell lysates and membrane fractions were prepared as previously
described (44). Immunoprecipitation with the antiinsulin receptor
ß-subunit antibody was carried out on membrane fractions as described
above. For immunoprecipitation of HA-ERK2, whole cell lysates (400 µg
total protein) were incubated with 7 µg HA-11 antibody and buffer
supplemented with 100 nM of okadaic acid at 4 C on a
rotating wheel. After 2 h, protein G-agarose was added (5% of
total volume) and the samples were incubated overnight at 4 C on a
rotating wheel. Samples were then treated as described above and
immunoblotted with antibodies against the HA-tag or phospho-MAPK.
Quantification of phospho-ERK2 was performed using a laser scanning
densitometer (Molecular Dynamics, Inc., Sunnyvale,
CA).
125I-Labeled Insulin Binding
Tracer insulin binding to the cell surface of Cos-7 cells
transfected with various insulin receptor constructs was assessed at 4
C as previously described (45).
Phosphorylation of Elk-1
The Path-Detect System (Stratagene) was used to
assess the effects of overexpression of caveolin-1 on
insulin-stimulated phosphorylation of Elk-1 in Cos-7 cells. In this
assay, phosphorylation of a transfected GAL4 binding domain/Elk-1
activation domain fusion protein results in activation of a
cotransfected GAL4 binding sequence/luciferase reporter plasmid
resulting in increased luciferase expression. The luciferase activity
was measured in cell lysates as previously described (46) and was
assumed to correlate with the level of Elk-1 phosphorylation.
Statistical Analysis
Paired Students t-tests were used for comparing
individual points where appropriate. P < 0.05 was
considered to signify statistical difference. The insulin dose-response
curves for GLUT4 translocation were fit using a nonlinear least squares
method and were compared by multiple ANOVA (MANOVA) as described
(44).
 |
ACKNOWLEDGMENTS
|
---|
We thank M. Lisanti for supplying the caveolin-1 cDNA and M.
Cobb for the HA-tagged ERK2. We also thank Simeon I. Taylor for helpful
discussions and for providing us with the human insulin receptor K1030A
mutant.
 |
FOOTNOTES
|
---|
Address requests for reprints to: Michael J. Quon, M.D., Ph.D., Hypertension-Endocrine Branch, National Heart, Lung, and Blood Institute, NIH, Building 10, Room 8C-103, 10 Center Drive MSC 1754, Bethesda, Maryland 20892-1754.
Received for publication June 17, 1999.
Revision received August 25, 1999.
Accepted for publication September 1, 1999.
 |
REFERENCES
|
---|
-
Hubbard SR, Wei L, Ellis L, Hendrickson WA 1994 Crystal
structure of the tyrosine kinase domain of the human insulin receptor.
Nature 372:746754[CrossRef][Medline]
-
Hanks SK, Quinn AM, Hunter T 1988 The protein kinase family:
conserved features and deduced phylogeny of the catalytic domains.
Science 241:4252[Medline]
-
Nystrom FH, Quon MJ 1999 Insulin signalling: metabolic
pathways and mechanisms for specificity. Cell Signal 11:563574[CrossRef][Medline]
-
Rothberg KG, Heuser JE, Donzell WC, Ying YS, Glenney JR,
Anderson RG 1992 Caveolin, a protein component of caveolae membrane
coats. Cell 68:673682[Medline]
-
Shaul PW, Anderson RG 1998 Role of plasmalemmal caveolae in
signal transduction. Am J Physiol 275:L843851
-
Tang Z, Scherer PE, Okamoto T, Song K, Chu C, Kohtz DS,
Nishimoto I, Lodish HF, Lisanti MP 1996 Molecular cloning of
caveolin-3, a novel member of the caveolin gene family expressed
predominantly in muscle. J Biol Chem 271:22552261[Abstract/Free Full Text]
-
Scherer PE, Lewis RY, Volonte D, Engelman JA, Galbiati F,
Couet J, Kohtz DS, van Donselaar E, Peters P, Lisanti MP 1997 Cell-type
and tissue-specific expression of caveolin-2. Caveolins 1 and 2
co-localize and form a stable hetero-oligomeric complex in
vivo. J Biol Chem 272:2933729346[Abstract/Free Full Text]
-
Okamoto T, Schlegel A, Scherer PE, Lisanti MP 1998 Caveolins,
a family of scaffolding proteins for organizing "preassembled
signaling complexes" at the plasma membrane. J Biol Chem 273:54195422[Free Full Text]
-
Li S, Song KS, Koh SS, Kikuchi A, Lisanti MP 1996 Baculovirus-based expression of mammalian caveolin in Sf21 insect
cells. A model system for the biochemical and morphological study of
caveolae biogenesis. J Biol Chem 271:2864728654[Abstract/Free Full Text]
-
Yamamoto M, Toya Y, Schwencke C, Lisanti MP, Myers MG, Jr,
Ishikawa Y 1998 Caveolin is an activator of insulin receptor signaling.
J Biol Chem 273:2696226968[Abstract/Free Full Text]
-
Fan JY, Carpentier JL, van Obberghen E, Grunfeld C, Gorden P,
Orci L 1983 Morphological changes of the 3T3L1 fibroblast plasma
membrane upon differentiation to the adipocyte form. J Cell Sci 61:219230[Abstract]
-
Scherer PE, Lisanti MP, Baldini G, Sargiacomo M, Mastick CC,
Lodish HF 1994 Induction of caveolin during adipogenesis and
association of GLUT4 with caveolin-rich vesicles. J Cell Biol 127:12331243[Abstract]
-
Mastick CC, Saltiel AR 1997 Insulin-stimulated tyrosine
phosphorylation of caveolin is specific for the differentiated
adipocyte phenotype in 3T3L1 cells. J Biol Chem 272:2070620714[Abstract/Free Full Text]
-
Ribon V, Saltiel AR 1997 Insulin stimulates tyrosine
phosphorylation of the proto-oncogene product of c-Cbl in 3T3L1
adipocytes. Biochem J 324:839845[Medline]
-
Couet J, Sargiacomo M, Lisanti MP 1997 Interaction of a
receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding
negatively regulates tyrosine and serine/threonine kinase activities.
J Biol Chem 272:3042930438[Abstract/Free Full Text]
-
Moller DE, Yokota A, Ginsberg-Fellner F, Flier JS 1990 Functional properties of a naturally occurring Trp1200Ser1200
mutation of the insulin receptor. Mol Endocrinol 4:11831191[Abstract]
-
Moller DE, Benecke H, Flier JS 1991 Biologic activities of
naturally occurring human insulin receptor mutations. Evidence that
metabolic effects of insulin can be mediated by a kinase-deficient
insulin receptor mutant. J Biol Chem 266:1099511001[Abstract/Free Full Text]
-
Iwanishi M, Haruta T, Takata Y, Ishibashi O, Sasaoka T, Egawa
K, Imamura T, Naitou K, Itazu T, Kobayashi M 1993 A mutation
(Trp1193>Leu1193) in the tyrosine kinase domain of the insulin
receptor associated with type A syndrome of insulin resistance.
Diabetologia 36:414422[Medline]
-
Imamura T, Takata Y, Sasaoka T, Takada Y, Morioka H, Haruta T,
Sawa T, Iwanishi M, Hu YG, Suzuki Y, Hamada J, Kobayashi M 1994 Two naturally occurring mutations in the kinase domain of insulin
receptor accelerate degradation of the insulin receptor and impair the
kinase activity. J Biol Chem 269:3101931027[Abstract/Free Full Text]
-
Sawa T, Imamura T, Haruta T, Sasaoka T, Ishiki M, Takata Y,
Takada Y, Morioka H, Ishihara H, Usui I, Kobayashi M 1996 Hsp70 family
molecular chaperones and mutant insulin receptor: differential binding
specificities of BiP and Hsp70/Hsc70 determines accumulation or
degradation of insulin receptor. Biochem Biophys Res Commun 218:449453[CrossRef][Medline]
-
Imamura T, Haruta T, Takata Y, Usui I, Iwata M, Ishihara H,
Ishiki M, Ishibashi O, Ueno E, Sasaoka T, Kobayashi M 1998 Involvement
of heat shock protein 90 in the degradation of mutant insulin receptors
by the proteasome. J Biol Chem 273:1118311188[Abstract/Free Full Text]
-
Quon MJ, Guerre-Millo M, Zarnowski MJ, Butte AJ, Em M, Cushman
SW, Taylor SI 1994 Tyrosine kinase-deficient mutant human insulin
receptors (Met1153 >Ile) overexpressed in transfected rat adipose
cells fail to mediate translocation of epitope-tagged GLUT4. Proc Natl
Acad Sci USA 91:55875591[Abstract]
-
Smith RM, Jarett L 1988 Receptor-mediated endocytosis and
intracellular processing of insulin: ultrastructural and biochemical
evidence for cell-specific heterogeneity and distinction from
nonhormonal ligands. Lab Invest 58:613629[Medline]
-
Smith RM, Harada S, Smith JA, Zhang S, Jarett L 1998 Insulin-induced protein tyrosine phosphorylation cascade and signalling
molecules are localized in a caveolin-enriched cell membrane domain.
Cell Signal 10:355362[CrossRef][Medline]
-
Hubbard SR 1997 Crystal structure of the activated insulin
receptor tyrosine kinase in complex with peptide substrate and ATP
analog. EMBO J 16:55725581[Abstract/Free Full Text]
-
Li S, Couet J, Lisanti MP 1996 Src tyrosine kinases, G
subunits, and H-Ras share a common membrane-anchored scaffolding
protein, caveolin. Caveolin binding negatively regulates the
auto-activation of Src tyrosine kinases. J Biol Chem 271:2918229190[Abstract/Free Full Text]
-
Ghosh S, Gachhui R, Crooks C, Wu C, Lisanti MP, Stuehr DJ 1998 Interaction between caveolin-1 and the reductase domain of endothelial
nitric-oxide synthase. Consequences for catalysis. J Biol Chem 273:2226722271[Abstract/Free Full Text]
-
Koleske AJ, Baltimore D, Lisanti MP 1995 Reduction of caveolin
and caveolae in oncogenically transformed cells. Proc Natl Acad Sci USA 92:13811385[Abstract]
-
Engelman JA, Lee RJ, Karnezis A, Bearss DJ, Webster M, Siegel
P, Muller WJ, Windle JJ, Pestell RG, Lisanti MP 1998 Reciprocal
regulation of neu tyrosine kinase activity and caveolin-1 protein
expression in vitro and in vivo. Implications for
human breast cancer. J Biol Chem 273:2044820455[Abstract/Free Full Text]
-
Galbiati F, Volonte D, Engelman JA, Watanabe G, Burk R,
Pestell RG, Lisanti MP 1998 Targeted downregulation of caveolin-1 is
sufficient to drive cell transformation and hyperactivate the p42/44
MAP kinase cascade. EMBO J 17:66336648[Abstract/Free Full Text]
-
Engelman JA, Wykoff CC, Yasuhara S, Song KS, Okamoto T,
Lisanti MP 1997 Recombinant expression of caveolin-1 in oncogenically
transformed cells abrogates anchorage-independent growth. J Biol
Chem 272:1637416381[Abstract/Free Full Text]
-
Song SK, Li S, Okamoto T, Quilliam LA, Sargiacomo M, Lisanti
MP 1996 Co-purification and direct interaction of Ras with caveolin, an
integral membrane protein of caveolae microdomains. Detergent-free
purification of caveolae microdomains. J Biol Chem 271:96909697[Abstract/Free Full Text]
-
Lavie Y, Fiucci G, Liscovitch M 1998 Up-regulation of caveolae
and caveolar constituents in multidrug-resistant cancer cells. J
Biol Chem 273:3238032383[Abstract/Free Full Text]
-
Yang CP, Galbiati F, Volonte D, Horwitz SB, Lisanti MP 1998 Upregulation of caveolin-1 and caveolae organelles in Taxol-resistant
A549 cells. FEBS Lett 439:368372[CrossRef][Medline]
-
Nasu Y, Timme TL, Yang G, Bangma CH, Li L, Ren C, Park SH,
DeLeon M, Wang J, Thompson TC 1998 Suppression of caveolin expression
induces androgen sensitivity in metastatic androgen-insensitive mouse
prostate cancer cells. Nat Med 4:10621064[CrossRef][Medline]
-
Liu P, Ying Y, Anderson RG 1997 Platelet-derived growth factor
activates mitogen-activated protein kinase in isolated caveolae. Proc
Natl Acad Sci USA 94:1366613670[Abstract/Free Full Text]
-
Bandyopadhyay G, Standaert ML, Kikkawa U, Ono Y, Moscat
J, Farese RV 1999 Effects of transiently expressed atypical (
,
),
conventional (
, ß) and novel (
,
) protein kinase C isoforms
on insulin-stimulated translocation of epitope-tagged GLUT4 glucose
transporters in rat adipocytes: specific interchangeable effects of
protein kinases C-
and C-
. Biochem J 337:461470[CrossRef][Medline]
-
Oka N, Yamamoto M, Schwencke C, Kawabe J, Ebina T, Ohno S,
Couet J, Lisanti MP, Ishikawa Y 1997 Caveolin interaction with protein
kinase C. Isoenzyme-dependent regulation of kinase activity by the
caveolin scaffolding domain peptide. J Biol Chem 272:3341633421[Abstract/Free Full Text]
-
Mastick CC, Brady MJ, Saltiel AR 1995 Insulin stimulates the
tyrosine phosphorylation of caveolin. J Cell Biol 129:15231531[Abstract]
-
Choi T, Huang M, Gorman C, Jaenisch R 1991 A generic intron
increases gene expression in transgenic mice. Mol Cell Biol 11:30703074[Medline]
-
Quon MJ, Zarnowski MJ, Guerre-Millo M, de la Luz Sierra M,
Taylor SI, Cushman SW 1993 Transfection of DNA into isolated rat
adipose cells by electroporation: evaluation of promoter activity in
transfected adipose cells which are highly responsive to insulin after
one day in culture. Biochem Biophys Res Commun 194:338346[CrossRef][Medline]
-
Scherer PE, Tang Z, Chun M, Sargiacomo M, Lodish HF, Lisanti
MP 1995 Caveolin isoforms differ in their N-terminal protein
sequence and subcellular distribution. Identification and epitope
mapping of an isoform-specific monoclonal antibody probe. J
Biol Chem 270:1639516401[Abstract/Free Full Text]
-
Quon MJ, Butte AJ, Zarnowski MJ, Sesti G, Cushman SW, Taylor
SI 1994 Insulin receptor substrate 1 mediates the stimulatory effect of
insulin on GLUT4 translocation in transfected rat adipose cells. J
Biol Chem 269:2792027924[Abstract/Free Full Text]
-
Chen H, Wertheimer SJ, Lin CH, Katz SL, Amrein KE, Burn P,
Quon MJ 1997 Protein-tyrosine phosphatases PTP1B and syp are modulators
of insulin- stimulated translocation of GLUT4 in transfected rat
adipose cells. J Biol Chem 272:80268031[Abstract/Free Full Text]
-
Quon MJ, Cama A, Taylor SI 1992 Postbinding characterization
of five naturally occurring mutations in the human insulin receptor
gene: impaired insulin-stimulated c-jun expression and thymidine
incorporation despite normal receptor autophosphorylation. Biochemistry 31:99479954[Medline]
-
Chen H, Srinivas PR, Cong LN, Li Y, Grunberger G, Quon MJ 1998 Alpha2-Heremans Schmid glycoprotein inhibits insulin-stimulated Elk-1
phosphorylation, but not glucose transport, in rat adipose cells.
Endocrinology 139:41474154[Abstract/Free Full Text]